Mylan (MYL) Receives Coverage Optimism Rating of 0.19
Media coverage about Mylan (NASDAQ:MYL) has been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mylan earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.3593189191881 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Mylan (MYL) PT Raised to $51.00 (americanbankingnews.com)
- Commit To Purchase Mylan At $32.50, Earn 5.2% Annualized Using Options – Nasdaq (nasdaq.com)
- Mylan NV Stock Is Headed Back Down to $40 – Investorplace.com (investorplace.com)
- Global Hormone Replacement Therapy (HRT) Market 2018 Abbott Laboratories, Novartis, Pfizer, Mylan Laboratories (lincolntrailpublishing.com)
- Should Value Investors Pick Mylan (MYL) Stock? (zacks.com)
Shares of Mylan (NASDAQ:MYL) traded up $0.06 during trading on Friday, hitting $41.73. The company’s stock had a trading volume of 7,038,873 shares, compared to its average volume of 4,658,225. Mylan has a 12 month low of $29.39 and a 12 month high of $47.82. The company has a market capitalization of $21,450.95, a P/E ratio of 32.35, a P/E/G ratio of 1.32 and a beta of 1.35. The company has a quick ratio of 0.73, a current ratio of 1.13 and a debt-to-equity ratio of 1.06.
MYL has been the topic of several analyst reports. Cantor Fitzgerald set a $41.00 target price on Mylan and gave the company a “hold” rating in a research note on Tuesday, December 26th. Zacks Investment Research lowered Mylan from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. UBS set a $46.00 target price on Mylan and gave the company a “buy” rating in a research note on Monday, December 4th. Susquehanna Bancshares reissued a “positive” rating and issued a $55.00 target price (up previously from $47.00) on shares of Mylan in a research note on Thursday, January 25th. Finally, Morgan Stanley raised Mylan from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $39.00 to $50.00 in a research note on Tuesday, March 6th. Nine research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $46.62.
In related news, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anthony Mauro sold 12,257 shares of the stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $40.35, for a total value of $494,569.95. Following the transaction, the insider now owns 147,435 shares of the company’s stock, valued at $5,949,002.25. The disclosure for this sale can be found here. Insiders sold 344,287 shares of company stock valued at $14,409,960 over the last 90 days. Corporate insiders own 0.69% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Mylan (MYL) Receives Coverage Optimism Rating of 0.19” was first posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2018/03/17/mylan-myl-receives-coverage-optimism-rating-of-0-19.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.